Program
HDM2005
A development code. Also written as “Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len”, “Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len” and “HDM2005 plus rituximab and lenalidomide”.
Its studies are mostly in Lymphoma, Mantle-Cell · Lymphoma, led by Huadong Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 33 open or running | phase 1since Sep 19, 2024 | Sep 19, 2024 | Jul 1, 2027phase 1 · NCT07004296 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2024First study: phase 1 study in LymphomaFirst studyNCT06615193 · 111 planned · China
- May 27, 2025Phase 1 study in Advanced Solid TumorsNCT07004296 · 72 planned · China
- Jul 2, 2026Phase 1 study in Lymphoma, Mantle-CellNCT07697339 · 40 planned
Ahead
- Jul 1, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT07004296
- Aug 10, 2027Primary completion: phase 1 study in Lymphoma, Mantle-CellNCT07697339
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07697339Lymphoma, Mantle-Cell | 1 | Not yet recruiting | Aug 10, 2027 | 40 |
| NCT07004296Advanced Solid Tumors · China | 1 | Recruiting | Jul 1, 2027 | 72 |
| NCT06615193Lymphoma · China | 1 | Recruiting | Jun 24, 2026 | 111 |
How it is read
Names in the registry
- “HDM2005”, 2 entries
- “Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len”, 1 entry
- “Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len”, 1 entry
- “HDM2005 plus rituximab and lenalidomide”, 1 entry
Codes read as this program: HDM2005.
Conditions, from the studies’ own filings
- Lymphoma, Mantle-Cell, 1 study
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.